EP 0737070 A1 19961016 - VITAMIN D 3? ANALOGUES AND PATHWAY TO MEDIATE DISORDERS
Title (en)
VITAMIN D 3? ANALOGUES AND PATHWAY TO MEDIATE DISORDERS
Title (de)
VITAMIN D3-ANALOGA UND WEG ZUR VERMITTLUNG VON ERKRANKUNGEN
Title (fr)
ANALOGUES DE VITAMINES D 3? ET VOIE INDUISANT DES TROUBLES
Publication
Application
Priority
- US 9414870 W 19941223
- US 17356193 A 19931223
- US 24938594 A 19940525
Abstract (en)
[origin: WO9517197A1] Methods for controlling genomic and nongenomic cellular responses which are mediated by 1 alpha ,25-(OH)2 vitamin D3[1 alpha ,25-(OH)2D3]. The method involves treating cells which exhibit nongenomic responses to 1 alpha ,25-(OH)2D3 with the vitamin C3 analogues 1,25(OH)2-previtamin D3 or 1 beta ,25-(OH)2 vitamin D3 [1 beta ,25-(OH)2D3]. The 1,25(OH)2-previtamin D3 functions as an agonist to promote the cellular response while the 1 beta ,25-(OH)2D3 functions as an antagonist. Transcaltachia is one of the nongenomic responses which is affected and can be controlled by administration of 1,25(OH)2-previtamin D3 or 1 beta ,25-(OH)2D3. Fifteen additional analogues are disclosed which may be used to control genomic and/or nongenomic cellular responses.
IPC 1-7
IPC 8 full level
A61K 31/575 (2006.01); A61K 31/59 (2006.01); A61P 3/02 (2006.01); A61P 17/00 (2006.01); A61P 25/28 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); A61P 43/00 (2006.01)
CPC (source: EP)
A61K 31/575 (2013.01); A61K 31/59 (2013.01); A61P 3/02 (2017.12); A61P 17/00 (2017.12); A61P 25/28 (2017.12); A61P 35/00 (2017.12); A61P 35/02 (2017.12); A61P 43/00 (2017.12)
Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 9517197 A1 19950629; AU 1445295 A 19950710; CA 2179288 A1 19950629; EP 0737070 A1 19961016; EP 0737070 A4 19990317; JP H09507079 A 19970715
DOCDB simple family (application)
US 9414870 W 19941223; AU 1445295 A 19941223; CA 2179288 A 19941223; EP 95906111 A 19941223; JP 51763195 A 19941223